Alembic Pharmaceuticals Secures USFDA Nod for Seizure Drug
Alembic Pharmaceuticals Secures USFDA Nod for Seizure Drug is drawing significant interest across the industry.
Alembic Pharmaceuticals has received US FDA approval to market generic Lamotrigine orally disintegrating tablets for seizures. The drug is equivalent to GlaxoSmithKline's Lamictal and is approved for various types of seizures. Market size is estimated at USD 27 million by 2025.
Experts suggest this could influence future trends and innovation in the sector.
More updates are expected as the story develops.
Related Articles
- ACC Women's Asia Cup Rising Stars 2026 Guide: Full Schedule, Groups, Venue, Live Streaming - All You Need To Know
- source at scale across hybrid and multicloud environments
- Someone wrote a travel guide to 'fashionable' Swansea 200 years ago and made a shocking statement
- Paramount announces official merger agreement to acquire WBD
Source: Original →